Table 1 Demographic and clinical data for the Memory Malmö ‘discovery’ cohort
From: Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease
Control Aβ- | Control Aβ+ | MCI- Aβ- | MCI- Aβ+ | AD (Aβ+) | P-valuea (group differences) | |
|---|---|---|---|---|---|---|
Sample size (n) | 415 | 142 | 50 | 75 | 161 | |
Sex (F/M) | 256/159 | 100/42 | 20/30 | 33/42 | 104/57 | 0.000061 |
Mean age in years (SD) | 71.7 (5.21) | 72.99 (4.78) | 68.8 (5.12) | 72.29 (4.93) | 74.58 (7.37) | 1.676 × 10−10 |
MMSE mean (SD) | 29.11 (0.9) | 29.02 (0.83) | 27.3 (1.68) | 26.56 (1.79) | 21.47 (3.9) | 9.4022 × 10−213 |
APOE (1 or 2 ɛ4 alleles) | 22.89% | 57.75% | 20% | 74.67% | 66.46% | 7.0724 × 10−32 |
Anti-inflammatory drugs | 9.64% | 7.75% | 4.00% | 9.33% | 6.21% | 0.52 |
Platelet inhibitor drugs | 16.39% | 17.61% | 38.00% | 33.33% | 29.19% | 0.000016 |
Antidepressive drugs | 6.75% | 7.04% | 32.00% | 16.00% | 22.98% | 1.3371 × 10−10 |
Lipid-lowering drugs | 26.02% | 30.99% | 42.00% | 37.33% | 29.81% | 0.07 |
Antihypertensive/cardioprotective drugs | 41.69% | 49.30% | 54% | 52% | 54.04% | 0.04 |
Current smoker | 9.4% | 2.82% | 8% | 5.33% | 9.94% | 0.08 |
Mean Aβ42 in pg/ml (SD) | 752 (253) | 423 (175) | 628 (223) | 280 (90) | 305 (132) | 6.3545 × 10− 119 |
Mean Aβ40 in pg/ml (SD) | 5847 (2042) | 6566 (2373) | 4956 (2045) | 5057 (1612) | 5470 (2179) | 4.9837 × 10−8 |
Aβ42/40 ratio - log2 transformed (SD) | 2.05 (0.17) | 2.75 (0.28) | 2.05 (0.17) | 2.89 (0.28) | 2.9 (0.29) | 7.8397 × 10−253 |
Mean total tau (SD) | 292 (89) | 432 (163) | 295 (110) | 515 (181) | 649 (221) | |
Mean phospho-tau (SD) | 37 (13) | 66 (35) | 40 (17) | 105 (46) | 123 (47) |